Wall Street analyst price targets, ratings consensus & upside potential · Updated Feb 28, 2026
Last 12 months price action with 12-month analyst target path
As of February 28, 2026, Humana Inc. (HUM) has a Wall Street consensus price target of $235.00, based on estimates from 43 covering analysts. With the stock currently trading at $190.54, this represents a potential upside of +23.3%. The company has a market capitalization of $22.92B.
Analyst price targets range from a low of $146.00 to a high of $345.00, representing a 85% spread in expectations. The median target of $220.00 differs from the mean, suggesting potential outlier estimates. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Hold, with 13 analysts rating the stock as a Buy or Strong Buy,28 rating it Hold, and 2 rating it Sell or Strong Sell. The mixed ratings reflect uncertainty about near-term direction.
From a valuation perspective, HUM trades at a trailing P/E of 19.1x and forward P/E of 19.9x. Analysts expect EPS to grow -10.3% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $339.27, with bear and bull scenarios of $231.52 and $1605.31 respectively. Model confidence stands at 74/100, indicating high predictability in the company's fundamentals.
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how HUM stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonThe consensus Wall Street price target for HUM is $235, representing 23.3% upside from the current price of $190.54. With 43 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
HUM has a consensus rating of "Hold" based on 43 Wall Street analysts. The rating breakdown is mixed, with 28 Hold ratings making up the largest segment. The consensus 12-month price target of $235 implies 23.3% upside from current levels.
With a forward P/E of 19.8738x, HUM trades at a relatively low valuation. The consensus target of $235 implies 23.3% appreciation, suggesting meaningful undervaluation.
The most bullish Wall Street analyst has a price target of $345 for HUM, while the most conservative target is $146. The consensus of $235 represents the median expectation. Our quantitative valuation model projects a bull case target of $1605 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
HUM is heavily covered by Wall Street, with 43 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 13 have Buy ratings, 28 recommend Hold, and 2 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month HUM stock forecast based on 43 Wall Street analysts shows a consensus price target of $235, with estimates ranging from $146 (bear case) to $345 (bull case). The median consensus rating is "Hold". Our proprietary valuation model produces a base case fair value of $339, with bear/bull scenarios of $232/$1605.
Our quantitative valuation model calculates HUM's fair value at $339 (base case), with a bear case of $232 and bull case of $1605. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 74/100.
HUM trades at a forward P/E ratio of 19.9x based on next-twelve-months earnings estimates compared to a trailing P/E of 19.1x. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are very optimistic on HUM, with a "Hold" consensus rating and $235 price target (23.3% upside). 13 of 43 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
HUM analyst price targets range from $146 to $345, a 85% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $235 consensus represents the middle ground. Our model's $232-$1605 range provides an independent fundamental perspective.